ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

AGEN Agenus Inc

11.78
3.48 (41.93%)
27 4월(4) 2024 - 마감
15분 지연
기업명 주식 심볼 시장 주식 타입
Agenus Inc AGEN 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
3.48 41.93% 11.78 13:00:02
개장가 저가 고가 종가 전일 종가
8.55 8.45 12.23 11.69 8.30
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
24/04/202423:00BWBotensilimab/Balstilimab Data in MSS CRC Selected for the..
23/04/202420:30BWAgenus to Provide First Quarter 2024 Financial Report and..
12/04/202420:30BWAgenus Announces Updated Phase 1 Data and Progress on..
06/04/202405:30BWAgenus Announces Reverse Stock Split of Common Stock
14/03/202420:30BWAgenus Reports Fourth Quarter and Full Year 2023 Results
06/03/202421:30BWAgenus Announces Preclinical Data on BMS-986442 (AGEN1777)..
06/03/202406:30BWAgenus Reports Inducement Grants Under Nasdaq Listing Rule..
01/03/202406:50EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
29/02/202421:30BWAgenus to Provide Corporate Update and Fourth Quarter & Full..
27/02/202406:24EDGAR2Form DEF 14A - Other definitive proxy statements
26/02/202421:30BWAgenus to Participate in Leerink Partners Global Biopharma..
15/02/202422:02EDGAR2Form PRE 14A - Other preliminary proxy statements
15/02/202422:00EDGAR2Form 8-K - Current report
15/02/202421:02PRNUSGinkgo Bioworks and SaponiQx Awarded MCDC Contract to..
14/02/202422:33EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/02/202421:00EDGAR2Form 5 - Annual statement of changes in beneficial ownership..
10/02/202407:11EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
31/01/202422:00EDGAR2Form 8-K - Current report
31/01/202421:30BWAgenus to Participate in Oppenheimer 34th Annual Healthcare..
22/01/202423:59BWBotensilimab/Balstilimab Breakthrough Data Presented at..
22/01/202421:30BWBotensilimab/Balstilimab Breakthrough Data Presented at..
06/01/202406:30BWAgenus Reports Inducement Grants Under Nasdaq Listing Rule..
04/01/202421:30BWAgenus to Participate in B. Riley Healthcare Conference
04/01/202420:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/01/202420:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/01/202420:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202321:30BWBotensilimab/Balstilimab Data in Neoadjuvant Colorectal..
11/12/202321:30BWAgenus to Receive $25 Million Milestone Payment from Bristol..
09/12/202306:15EDGAR2Form 8-K - Current report
18/11/202306:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/11/202306:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202320:30EDGAR2Form 8-K - Current report
07/11/202320:30BWAgenus Reports Third Quarter 2023 Results
26/10/202322:05BWAgenus to Provide Third Quarter 2023 Financial Report and..
23/10/202301:00BWAgenus Unveils New and Updated Botensilimab Data in..
21/10/202317:15BWESMO 2023: Agenus’ Botensilimab/Balstilimab Combination..
17/10/202306:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/10/202320:30BWAgenus Completes Enrollment in Randomized Phase 2 Clinical..
07/10/202305:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/10/202320:30BWAgenus To Host BOT/BAL Program Update at ESMO 2023
05/10/202306:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/10/202306:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/10/202306:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/09/202305:30BWAgenus Reports Inducement Grants Under Nasdaq Listing Rule..
01/09/202306:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/08/202306:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/08/202320:30BWAgenus to Participate in September Investor Conferences
23/08/202321:00EDGAR2Form 8-K - Current report
23/08/202321:00BWAgenus Prioritizes Resources to Accelerate Registration and..
09/08/202321:30BWSaponiQx Announces Breakthrough in Scaling Up of STIMULON™..

최근 히스토리

Delayed Upgrade Clock